Analyzing...
Loading company...
SeQuent Scientific Ltd. manufactures and produces veterinary pharmaceuticals and specialty chemicals. The company is headquartered in Bangalore, Karnataka and currently employs 1,958 full-time employees. The company went IPO on 2016-03-10. The firm operates in the domains of animal health, in which it provides active pharmaceutical ingredient (APIs) and finished dosage formulations, and analytical services. The firm through its subsidiary, Alivira Animal Health Limited, offers APIs and formulations. Alivira Animal Health Limited has manufacturing facilities in five countries, including India. The Company’s subsidiary, Sequent Research Limited, is a contract research organization, which is engaged in analytical and biological analytical services to support the API, pharmaceutical, personal care and nutraceutical companies. Sequent Research Limited provides complete analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopeial monographs, customer-developed methods or in-house method development.
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹3,420 Cr revenue.
COGS 45.7%, employees 16.5%.
“we are confident, and we are targeting minimum of 20% EBITDA growth.”
“Looking at our current day, two hundred hour growth is nothing actually for this company.”
“Revenue from operations for Q3 FY26 was INR858 crores, grown up by 11% year on year.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 6.1%▼ | 10.3% |
| ROCE | 11.4%▼ | 13.7% |
| Net Margin | 5.1%▼ | 7.6% |
| EBITDA Margin | 18.8%▲ | 15.4% |
| Debt To Equity | 0.15x▼ | 0.15x |
| Rev Growth 3yr | 34.4%▲ | 10.0% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2,644 Cr +70.4% | ₹1,551 Cr +13.3% | ₹1,370 Cr -3.6% | ₹1,421 Cr +0.6% | ₹1,413 Cr +3.8% | ₹1,362 Cr +15.5% | ₹1,179 Cr +13.5% | ₹1,039 Cr |
| Other Income | ₹36 Cr +144.5% | ₹15 Cr +34.1% | ₹11 Cr +71.5% | ₹6 Cr -41.1% | ₹11 Cr +29.7% | ₹8 Cr -17.1% | ₹10 Cr +16.3% | ₹9 Cr |
| Total Income | ₹2,680 Cr +71.1% | ₹1,566 Cr +13.4% | ₹1,381 Cr -3.3% | ₹1,427 Cr +0.3% | ₹1,424 Cr +3.9% | ₹1,370 Cr +15.2% | ₹1,189 Cr +13.5% | ₹1,048 Cr |
| COGS | ₹1,251 Cr +54.1% | ₹812 Cr +6.9% | ₹760 Cr -8.9% | ₹834 Cr +5.1% | ₹793 Cr +14.2% | ₹695 Cr +14.8% | ₹605 Cr +11.4% | ₹543 Cr |
| ₹2,385 Cr +57.2% | ₹1,517 Cr +7.0% | ₹1,418 Cr -5.5% | ₹1,500 Cr +9.5% | ₹1,370 Cr +11.9% | ₹1,225 Cr +11.8% | ₹1,095 Cr +10.7% | ₹989 Cr | |
| Profit Before Tax | ₹251 Cr +466.4% | ₹44 Cr ↑ Recovery | (₹55 Cr) +60.3% | (₹138 Cr) ↓ Decline | ₹53 Cr -60.9% | ₹137 Cr +45.2% | ₹94 Cr +59.8% | ₹59 Cr |
| Exceptional Items | (₹44 Cr) -789.5% | (₹5 Cr) +71.4% | (₹17 Cr) +73.2% | (₹65 Cr) | ₹0.00 Cr +100.0% | (₹9 Cr) | ₹0.00 Cr | ₹0.00 Cr |
| ₹99 Cr +720.9% | ₹12 Cr ↑ Recovery | (₹25 Cr) -59.6% | (₹16 Cr) ↓ Decline | ₹8 Cr -74.1% | ₹32 Cr +167.5% | ₹12 Cr +499.4% | ₹2 Cr | |
| Net Profit | ₹152 Cr +371.4% | ₹32 Cr ↑ Recovery | (₹30 Cr) +75.7% | (₹122 Cr) ↓ Decline | ₹45 Cr -56.9% | ₹104 Cr +27.3% | ₹82 Cr +44.3% | ₹57 Cr |
| Profit (Owners) | ₹120 Cr +446.6% | ₹22 Cr ↑ Recovery | (₹36 Cr) +70.4% | (₹121 Cr) ↓ Decline | ₹41 Cr -56.8% | ₹95 Cr +36.5% | ₹70 Cr +43.7% | ₹49 Cr |
| Minority Interest | ₹32 Cr +212.8% | ₹10 Cr +65.9% | ₹6 Cr ↑ Recovery | (₹0.82 Cr) ↓ Decline | ₹4 Cr -57.7% | ₹9 Cr -25.8% | ₹12 Cr +47.8% | ₹8 Cr |
| Other Comprehensive Income | ₹88 Cr ↑ Recovery | (₹22 Cr) +66.8% | (₹65 Cr) -149.2% | (₹26 Cr) +75.9% | (₹109 Cr) ↓ Decline | ₹64 Cr ↑ Recovery | (₹32 Cr) +40.8% | (₹54 Cr) |
| EPS | ₹3.23 | ₹0.87 | (₹1.44) | (₹4.86) | ₹1.66 | ₹3.84 | ₹2.81 | ₹1.97 |
| Diluted Shares | ₹44 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Viyash Scientific Limited has informed the Exchange about ESOP Allotment
Viyash Scientific Limited has informed the Exchange about General Updates - Intimation under Regulation 30 of SEBILODR
Viyash Scientific Limited has informed the Exchange about Copy of Newspaper Publication- 41st AGM
Viyash Scientific Limited has informed the Exchange about letter to the shareholder
Viyash Scientific Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Report for the Financial Year 2025-26'.
Viyash Scientific Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 11, 2026
Viyash Scientific Limited has informed the Exchange about Copy of Newspaper Publication -AGM Notice
Viyash Scientific Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.
Viyash Scientific Limited has informed the Exchange about Schedule of meet
Viyash Scientific Limited has informed the Exchange regarding a press release dated Jun 08, 2026.
Viyash Scientific Limited has informed the Exchange about General Updates-Acquisition
Viyash Scientific Limited has informed the Exchange about Copy of Newspaper Publication
Viyash Scientific Limited has informed the Exchange about Transcript
Viyash Scientific Limited has informed the Exchange about Schedule of meet
Viyash Scientific Limited has informed the Exchange regarding Appointment of Appointment of Directors as Non- Executive Director of the company w.e.f. April 22, 2026.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
No dividend history available for this company.